Healthcare -
Biotechnology - NASDAQ - US
$ 0.049
31.7 %
$ 888 M
Market Cap
None
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart IMTXW
FINANCIALS
Balance Sheet
immatics biotechnologies GmbH
| Current Assets | 449 M |
| Cash & Short-Term Investments | 426 M |
| Receivables | 4.09 M |
| Other Current Assets | 19.4 M |
| Non-Current Assets | 60.6 M |
| Long-Term Investments | 0 |
| PP&E | 57.1 M |
| Other Non-Current Assets | 3.54 M |
| Current Liabilities | 157 M |
| Accounts Payable | 7.67 M |
| Short-Term Debt | 2.6 M |
| Other Current Liabilities | 146 M |
| Non-Current Liabilities | 128 M |
| Long-Term Debt | 12.8 M |
| Other Non-Current Liabilities | 116 M |
EFFICIENCY
Earnings Waterfall
immatics biotechnologies GmbH
| Revenue | 54 M |
| Cost Of Revenue | 119 M |
| Gross Profit | -64.7 M |
| Operating Expenses | 156 M |
| Operating Income | -102 M |
| Other Expenses | -4.73 M |
| Net Income | -97 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
immatics biotechnologies GmbH
| Net Income | -97 M |
| Depreciation & Amortization | 7.23 M |
| Capital Expenditures | -31 M |
| Stock-Based Compensation | 20.7 M |
| Change in Working Capital | 81.6 M |
| Others | 90.3 M |
| Free Cash Flow | -12.7 M |
Wall Street Analysts Price Targets
immatics biotechnologies GmbH
IMTXW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
IMTXW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
immatics biotechnologies GmbH
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|
7. News
8. Profile
Summary
immatics biotechnologies GmbH IMTXW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 888 M
Dividend Yield
0.00%
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Contact
Paul-Ehrlich-Strasse 15, Tübingen, 72076
https://www.immatics.com
IPO
Date
July 2, 2020
Employees
542
Officers
Dr. Harpreet Singh Ph.D.
Chief Executive Officer, MD, Member of Management Board & Executive Director
Mr. Steffen Walter Ph.D.
Chief Operations Officer
Mr. Edward A. Sturchio
General Counsel & Secretary
Mr. Cedrik M. Britten M.D.
Chief Medical Officer
Mr. Jordan Silverstein
Head of Strategy
Dr. Carsten Reinhardt M.D., Ph.D.
Chief Development Officer
Dr. Hans-Georg Rammensee Ph.D.
Co-Founder & Member of the Scientific Advisory Board
Mr. Ephraim Hofsäß M.Sc.
Vice President of SEC Reporting & Accounting
Mr. Arnd Christ MBA
Chief Financial Officer
Dr. Toni Weinschenk Ph.D.
Co-Founder & Chief Innovation Officer